Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 9,630,000 shares, a growth of 18.6% from the October 15th total of 8,120,000 shares. Based on an average daily trading volume, of 991,100 shares, the short-interest ratio is presently 9.7 days.
Intellia Therapeutics Trading Up 11.1 %
Shares of NTLA stock opened at $26.45 on Wednesday. The company’s fifty day simple moving average is $30.31 and its 200-day simple moving average is $37.41. Intellia Therapeutics has a 52 week low of $22.67 and a 52 week high of $57.49. The company has a market cap of $2.37 billion, a PE ratio of -4.93 and a beta of 1.76.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last issued its earnings results on Thursday, November 9th. The company reported ($1.38) EPS for the quarter, beating analysts’ consensus estimates of ($1.52) by $0.14. The business had revenue of $11.99 million for the quarter, compared to the consensus estimate of $12.45 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 39.29%. The business’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.49) EPS. Equities research analysts expect that Intellia Therapeutics will post -5.64 EPS for the current fiscal year.
Analysts Set New Price Targets
Institutional Investors Weigh In On Intellia Therapeutics
Large investors have recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in shares of Intellia Therapeutics by 149.1% in the 1st quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $30,000 after purchasing an additional 474 shares during the last quarter. Sandia Investment Management LP bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $35,000. Jefferies Financial Group Inc. bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $38,000. ICA Group Wealth Management LLC bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $62,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Intellia Therapeutics by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after purchasing an additional 1,108 shares during the last quarter. 87.72% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.
- Five stocks we like better than Intellia Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Analyst says Archer Aviation may double. Is it time to buy?
- How to Invest in Mining Stocks
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- How to Invest in Solar Energy
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.